Vobarilizumab - Ablynx

Drug Profile

Vobarilizumab - Ablynx

Alternative Names: ALX 0061; ANTI-IL-6R; Anti-IL-6R Nanobody

Latest Information Update: 29 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Class Antirheumatics; Proteins
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 26 Mar 2018 Adverse events data from the phase II STEADY trial in Systemic lupus erythematosus released by Ablynx
  • 01 Jan 2018 Ablynx completes the STEADY trial in Systemic lupus erythematosus in USA, Argentina, Chile, Czech Republic, Germany, Hungary, South Korea, Mexico, Peru, Philippines, Poland, Portugal, Russia, Serbia, Spain, Taiwan and Ukraine (NCT02437890) (EudraCT2015-000372-95)
  • 15 Dec 2016 Ablynx completes enrolment in the phase II STEADY trial for Systemic lupus erythmatosus in USA, Hungary, Russia, Spain, Ukraine, Portugal, Poland, Serbia, Philippines, Taiwan, Mexico, Czech Republic, Germany, Chile and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top